Ceribell Inc (CBLL) 13F Positioning & Ownership Changes (Q2 2026)

CBLL ranks #4076 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CBLL is a top-conviction position for ABG-WTT Global Life Science Capital Partners GP Ltd — at 62.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CBLL belongs to FMR LLC, but the position matters far more to ABG-WTT Global Life Science Capital Partners GP Ltd, who has 62.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its CBLL position for two straight quarters, increasing it by $24.5M to reach $110.7M today.

Bank of New York Mellon Corp has trimmed its CBLL position for two straight quarters, cutting it by $9.4M while still holding $17.4M.

CBLL is up 0.9% today, and institutions have been net buyers of $23.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CBLL reported a net loss of $66.0M over the trailing twelve months.

• Not yet profitable — net loss of $66.0M over the trailing twelve months
• Revenue grew 31.7% year over year
• Net income declined year over year, from -$49.4M to -$66.0M
• Operating cash flow was negative, using $40.8M in cash
• Current ratio of 9.73x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.21x equity — within a conventional range